Sun Pharmaceutical Industries is India's most valuable pharmaceutical company — $5.1 billion in consolidated revenue (FY25), operations in 100+ countries, and a manufacturing network spanning 43 facilities globally. But the investment story that drove Sun's valuation from 2020-2025 is not the India generics business it was built on — it is the US specialty business that Dilip Shanghvi began building a decade ago.
The Specialty Transition
Sun's US business generates ~30-32% of total revenue. Within the US, the mix has shifted from commodity generics (where margins are compressed by competition) to branded specialty drugs. Ilumya (secukinumab for psoriasis), Cequa (cyclosporine for dry eye disease), and Winlevi (clascoterone for acne) are proprietary branded drugs with patent protection. Branded specialty drugs earn 60-80% gross margins vs 20-35% for generics. As specialty revenue grows as a share of US sales (currently ~35%), the blended margin profile improves structurally.
India Business: The Steady Foundation
Sun's India formulations business — the original core — continues to grow at 10-12% annually, driven by branded generics across chronic therapy areas (cardiology, psychiatry, neurology, ophthalmology). India contributes ~30% of consolidated revenue with EBITDA margins of ~25-27% — reliable, growing, but not the valuation driver.
- Consolidated revenue FY25: ~$5.1 billion
- US specialty revenue: ~35% of US sales (growing)
- India formulations growth: 10-12% annually
- Consolidated EBITDA margin: ~27-28%
- R&D spend: ~7-8% of revenue (specialty pipeline investment)
🔍 BBS Insight
Sun Pharma's valuation at 30-35x earnings is justified only if the specialty transition succeeds — meaning specialty revenue crosses 50% of US sales with improving margins. Track one metric every quarter: US specialty revenue as % of US total. If it is growing consistently, the re-rating thesis is intact. If it plateaus below 40%, Sun reverts to a generic pharma multiple (20-22x). The pipeline (Sun has multiple specialty Phase 2/3 assets) provides optionality — but pipeline optionality should not be in the base case valuation until approval.